首页> 外文期刊>Journal of chemotherapy >A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer
【24h】

A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer

机译:II期研究:剂量 - 致密的卡铂和紫杉醇作为局部晚期宫颈癌的新辅助化疗

获取原文
获取原文并翻译 | 示例
           

摘要

This study evaluates the efficacy and toxicity of dose-dense weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in locally advanced cervical cancer (LACC). We collected 23 cases of LACC treated with weekly paclitaxel and carboplatin for nine cycles: 20 patients had complete or partial response to chemotherapy and were submitted to surgery, 3 with poor response received chemoradiation therapy. Pathologic examination showed complete response in four patients, myometrial invasion 50% in nine and 50% in seven patients, parametrial involvement in two, vaginal metastasis in one and lymphovascular space invasion, with positive margins, in another case. Despite seven patients had radiological evidence of lymph nodes involvement at diagnosis, only one had nodal metastases. Five patients showed grade 3-4 of hematologic toxicity.
机译:本研究评估剂量密集的每周紫杉醇和卡铂作为局部晚期宫颈癌(LACC)的新辅助化疗的疗效和毒性。 我们收集了每周紫杉醇和卡铂治疗的23例LACC,九个循环:20名患者对化疗有完全或部分反应,并提交手术,3患者,应对较差的化学疗法。 病理检查显示出四名患者的完全反应,肌瘤侵袭患者九个患者50%,七名患者50%,患有淋巴血管空间侵袭的两个,阴道转移,在另一个案例中。 尽管7名患者有淋巴结的放射性证据参与诊断,但只有一个患有节点转移。 五名患者显示血液学毒性3-4级。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号